Abstract
alpha-Synuclein has been implicated in the pathophysiology of many neurodegenerative disorders, including Parkinson's disease (PD). In order to elucidate the role of this protein in the pathogenesis of PD, transgenic mice were created by using the tet-regulatable system driving the expression of human wildtype and mutated [A30P] alpha-synuclein in CNS neurons. Our studies demonstrate that the expression pattern depends on both the neuron-specific promoter and the integration site of the transgene constructs. Mice expressing high levels of human wildtype alpha-synuclein developed neuropathology and progressive motor impairment which could be stopped after blockade of expression in symptomatic mice. Mice expressing the mutated [A30P] alpha-synuclein restricted to the olfactory bulb showed significantly lower levels of dopamine and metabolites in this brain region. Thus our conditional mouse-model may help to define the role of human alpha-synuclein in synucleinopathies and might be used to demonstrate at which stage neuropathological symptoms of these diseases are reversible.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
